Generic Name and Formulations:
Diatrizoate meglumine 300mg/mL; soln for inj; contains organically bound iodine 141mg/mL.
Indications for CYSTOGRAFIN:
Take laxative night before exam; low residue diet day before. Individualize. Fill bladder with 25–300mL depending on age of patient and degree of bladder irritability; >300mL may be used if bladder capacity allows.
Severe sensitivity reactions may occur; have emergency equipment available. Bronchial asthma. Significant allergies. Active UTI. Pregnancy (Cat.C).
Radiopaque contrast agent.
May interfere with urine specimens.
Hypersensitivity reactions, hypothyroidism.
Bottles (100mL, 300mL)—1; Dilute (300mL)—10
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline